Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias
Menée notamment à l'aide de modèles murins ainsi que d'échantillons sanguins et d'échantillons de moelle osseuse d'origine humaine, cette étude met en évidence l'intérêt de lymphocytes CAR-T ciblant les protéines de liaison à l'ARN pour traiter des leucémies aiguës
Developing chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) has been challenging due to a lack of known AML-associated antigens that spare normal hematopoietic precursor cells. Here we reasoned that donor autoantibodies from AML recipients cured following allogeneic transplant and responsible for graft-versus-leukemia effect could be engineered to create effective CAR-T cells. We generated CAR-T cells against one such antigen - U5 snRNP200, an RNA helicase localized to the AML cell surface and absent from normal hematopoietic precursors. Anti-U5 snRNP200 CAR-T cells were effective in human and syngeneic models of AML as well as B-cell acute lymphoblastic leukemia (B-ALL), a setting where surface U5 snRNP200 is also present. Armoring CAR-T cells with IL-18 led to antigen gain on AML, durable remission, and protection from AML rechallenge. These data thereby identify a CAR-T cell platform which addresses prior limitations in tumor-selectivity and safety for patients with acute leukemias.
Cancer Discovery , article en libre accès, 2026